Cognition Therapeutics
CGTX0.90112.43% ( -0.0224 )
Cognition Therapeutics (CGTX)
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-...
- Open
- 0.9258
- High
- 0.9400
- Low
- 0.8800
- Prev. Close
- 0.9235
- Volume
- 350.54K
- Turnover
- 316.02K
- Avg Price
- 0.9015
- Bid/Ask Ratio
- --
- Amplitude
- 6.50%
- 52wk High
- 3.8300
- Volume Ratio
- 0.87
- Turnover Ratio
- 0.43%
Cognition Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 1, 2026Price forecast
$3.50288.41%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 hour ago
Cognition Therapeutics (CGTX) to Post Quarterly Earnings on Thursday
- Global Report · 2 hours ago
The Fringes of Wall Street: How Small-Cap Innovators and Niche Bets Are Navigating 2026
- Global Report · Jul 22 at 04:18 AM
US Equities Tracker: Restructuring and Pipeline Milestones Shape H2 2026
- Global Report · Jul 21 at 04:13 AM
The Unbundling of the Long Tail: Structural Realities at the Edges of the Value Chain
- PUBT · Jul 13 at 06:31 AM
Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website
- PUBT · Jun 25 at 08:02 AM
Hippo deploys Cognition’s Devin AI software engineer across insurance operations
